Waters Corporation income statement
In fiscal 2025, Waters Corporation reported revenue of $3.17bn, up 7.0% on the year before, operating income of $803m (a 25.4% margin) and net income of $643m, or $10.76 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJul 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,499 | 1,643 | 1,851 | 1,844 | 1,904 | 1,989 | 2,042 | 2,167 | 2,309 | 2,420 | 2,407 | 2,365 | 2,786 | 2,972 | 2,956 | 2,958 | 3,165 | 4,644 |
| Cost of revenue | 595 | 653 | 730 | 738 | 783 | 825 | 843 | 891 | 947 | 993 | 1,011 | 1,007 | 1,157 | 1,248 | 1,195 | 1,200 | 1,289 | — |
| Gross profit | 904 | 990 | 1,121 | 1,106 | 1,121 | 1,164 | 1,200 | 1,276 | 1,362 | 1,427 | 1,396 | 1,359 | 1,629 | 1,724 | 1,761 | 1,758 | 1,876 | — |
| Research and development | 77 | 84 | 92 | 96 | 101 | 108 | 119 | 125 | 133 | 143 | 143 | 141 | 168 | 176 | 175 | 183 | 196 | 319 |
| Selling, general and administrative | 421 | 445 | 490 | 477 | 493 | 513 | 496 | 512 | 544 | 537 | 535 | 554 | 627 | 658 | 736 | 690 | 830 | 1,246 |
| Operating income | 395 | 450 | 529 | 511 | 517 | 518 | 567 | 625 | 662 | 740 | 708 | 645 | 822 | 873 | 818 | 826 | 803 | 330 |
| Interest expense | 11 | 14 | 22 | 28 | 30 | 34 | 36 | 45 | 57 | 49 | 49 | 49 | 45 | 49 | 99 | 90 | 70 | 149 |
| Net interest income | — | — | — | — | — | — | — | — | — | — | — | — | — | −36 | −81 | −71 | −48 | — |
| Income before tax | 387 | 438 | 509 | 488 | 490 | 491 | 542 | 600 | 641 | 682 | 678 | 611 | 806 | 838 | 736 | 755 | 755 | 205 |
| Income tax | 63 | 56 | 76 | 26 | 40 | 59 | 73 | 79 | 621 | 88 | 86 | 89 | 113 | 130 | 94 | 117 | 112 | 39 |
| Net income | 323 | — | — | 461 | 450 | 432 | 469 | 522 | 20 | 594 | 592 | 522 | 693 | 708 | 642 | 638 | 643 | 166 |
| Diluted EPS | $3.34 | — | — | — | $5.20 | $5.07 | $5.65 | $6.41 | $0.25 | $7.65 | $8.69 | $8.36 | $11.17 | $11.73 | $10.84 | $10.71 | $10.76 | $2.22 |
| Diluted shares (average) | 97m | 94m | 92m | 89m | 87m | 85m | 83m | 81m | 81m | 78m | 68m | 62m | 62m | 60m | 59m | 60m | 60m | 75m |
| EBITDA | 426 | 484 | 565 | 549 | 556 | 564 | 613 | 677 | 724 | 798 | 762 | 714 | 893 | 945 | 902 | 913 | 891 | 445 |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Apr 2026 | 2026 Q2Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 740 | 873 | 662 | 771 | 800 | 932 | 1,267 | 1,645 |
| Cost of revenue | 302 | 349 | 277 | 321 | 328 | 363 | — | — |
| Gross profit | 439 | 524 | 385 | 450 | 472 | 569 | — | — |
| Research and development | 45 | 47 | 47 | 49 | 54 | 47 | 96 | 122 |
| Selling, general and administrative | 169 | 173 | 175 | 201 | 214 | 240 | 387 | 405 |
| Operating income | 211 | 292 | 152 | 188 | 192 | 271 | −47 | −86 |
| Interest expense | 21 | 19 | 14 | 14 | 27 | 14 | 48 | 60 |
| Net interest income | −18 | −15 | −9 | −11 | −22 | −6 | — | — |
| Income before tax | 194 | 277 | 143 | 178 | 170 | 264 | −88 | −141 |
| Income tax | 32 | 46 | 22 | 31 | 21 | 39 | −16 | −5 |
| Net income | 162 | 231 | 121 | 147 | 149 | 225 | −72 | −136 |
| Diluted EPS | $2.71 | $3.88 | $2.03 | $2.47 | $2.50 | $3.77 | −$0.87 | −$1.39 |
| EBITDA | 231 | 315 | 174 | 210 | 214 | 292 | −11 | −51 |
Compare with peers
- Illumina, Inc. income statement
- Mettler Toledo income statement
- Charles River Laboratories income statement
- Bruker Corp income statement
- Avantor, Inc. income statement
Head to head: ILMN vs WATMTD vs WATCRL vs WATAVTR vs WAT
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies